

Last Update: 2020-02-14

Remicade; infliximab

Target: TNF alpha antagonist**Class of Compound:** Rec chimeric IgG1 mab**Category:** Antibody**Company:** Johnson & Johnson (J&J) & Merck & Co.
(acquired Schering-Plough) & Mitsubishi Tanabe Pharma**Territory:** United States / Japan**Therapeutic Area:** Rheumatoid & autoimmune**Indication:** Moderately to severely active rheumatoid arthritis**Phase:** Market**Administration:****Drug Delivery:****Status:** Active**Approval US:** Approved**Approval UE:** Approved**Approval RoW:** Approved in Japan in 2002**Antibody Tech:****Protein Tech:****DNA Tech:****RNA Tech:****Cell Tech:****Vaccine Tech:****Partnering****Report Code:** LMCA0081 TB20 LMCA0114 LMCA0074**RDPN Code:** RDPN0645**Technology Code:****News**

Date	Title	Comments
2020-02-14	Merck Financial Disclosures Feb 5, 2020	2019 sales in Merck (intl.) territories of US\$ 411 mln (-29% vs previous year); 2019 sales in J&J territories of US\$ 4,380 mln (-16.8% vs previous year) source ; calendar year 2019 sales in JP by MTP of Yen 55.3 bln source corresponding to
2019-03-22	Merck Financial Highlightes FY 2018	2018 sales in Merck (non-US) territories of US\$ 582 mln (-31% vs previous year); J&J reported 2018 in J&J territories of US\$ 5,326 mln (-15.7% vs previous year) source ; calendar year 2018 calculated sales in MTP territory (JP) were Yen 59.4 bln (source);
2018-02-20	J&J PR Jan 23, 2018	2017 sales in J&J territories of US\$ 6,315 mln (-9.3% vs previous year); 2017 sales in Merck territories of US\$ 837 mln (-34% vs previous year) source ; calendar year 2017 sales in Japan by MTP of Yen 65.8 bln (-2.4% vs previous year) source
2017-03-14	J&J Product Sales 2016	2016 sales in J&J Territories of US\$ 6,966 mln (+6.2% vs 2015); 2016 sales in Merck territories of US\$ 1,268 mln (-29% vs 2015) source ; calendar year 2016 sales in Japan by MTP of Yen 67.4 bln source
2016-03-02	J&J Product Sales 2015	J&J reported mainly US 2015 sales of USD 6,561 mln (-4.5% vs previous year); 2015 sales in Merck territories were USD 1,794 mln (-24%) source ; calendar year 2015 sales by MTP were Yen 70.1 bln source corresponding to USD mln. Total sales =
2015-03-16	J&J Annual Report 2014	J&J reported 2014 sales of US\$ 6,868 mln (+2.9% vs previous year); 2014 sales in Merck territories were US\$ 2,372 mln (+4%) source ; calendar year 2014 sales in MTP territory were Yen 69.9 bln source .
2014-02-26	J&J Product Sales 2013	J&J reports 2013 US sales of US\$ 3,891 mln and intl sales of US\$ 1,443 mln (exports out of US were US\$ 1,339 mln); 2013 sales in Merck territories were US\$ 2,271 mln (+9%) source ; MTP sales in calendar year 2013 were Yen 78 bln source Total 2013 sales = US\$ 8,367 mln
2013-05-06	J&J PR Jan 22, 2013	J&J 2012 sales in the US were US\$ 3,583 mln and internationally US\$ 1,086 mln (and exports to partners in the value of US\$ 1,470 mln); 2012 sales in Merck territories were US\$ 2,076 mln source ; MTP sales in calendar year 2012 were Yen 71.8 bln source
2012-04-23	J&J PR Jan 24, 2012	2011 sales reported by J&J were US\$ 3,276 mln (+5.7 % vs previous year) in the US and US\$ 419 mln outside the US (J&J exported to partners for US\$ 1,797 mln); Merck & Co reported 2011 sales outside the US of US\$ 2,667 mln (-2% vs previous year) source ; MTP sales in calendar year 2011 were Yen 64.6 bln source
2011-02-28	J&J PR Jan 25, 2011	J&J US sales in 2010 were US\$ 3,099 mln (+0.4% vs previous) and exports to partners of US\$ 1,487 mln(+24.3% vs previous year); sales in Merck territories outside the US in 2010 were US\$ 2,714 mln (+ 17% vs previous year) source MTP sales in Apr-Dec 2010 were Yen 46.7 bln source and in Jan-Mar 2010 were Yen 11.3 bln source totalling Yen 58 bln in calendar year 2010

2010-11-09	Centocor Ortho Biotech PR Nov 8, 2010	Patients with active moderate to severe rheumatoid arthritis (RA) inadequately responding to either etanercept (Enbrel) or adalimumab (Humira) and who were actively switched to REMICADE (infliximab) demonstrated significant improvement from baseline at week 10, and sustained response through week 26 in an open label study
2010-03-10	Merck & Co 2009 Product Sales Feb 16, 2010	Merck & Co 2009 sales were US\$ 2,327 mln (+ 9.9 %); J&J recorded 2009 US sales of US\$ 3,088 mln (+ 9.9 % vs 2008) and exports to partners of US\$ 987 mln source Mitsubishi Tanabe Pharma's forecast of fiscal year 2009 sales are Yen 46.8 bln source corresponding to US\$ 519 mln. Total sales of US\$ 5,934 mln
2009-08-06	Food and Drug Administration (FDA) PR Aug 4, 2009	The FDA is requiring stronger warnings in the prescribing information for a class of drugs known as TNF blockers
2009-02-06	Schering-Plough PR Feb 3, 2009	2008 sales by Schering-Plough ex-US and ex-Japan (+ some Asian countries) were US\$ 2.118 bln (+ 28 %); MTP's forecast for FY 2008 sales based on 9-mths data are Yen 37.3 bln (about + 29 %) (= US\$ 407 mln) source J& reported 2008 US sales of US\$ 2.81 bln (+ 10.9 %) and exports to partners of US\$ 927 mln source Total Remicade 2008 sales = US\$ 5.335 bln
2009-01-29	FDA PR Sep 04, 2008	FDA alerts manufacturers about the risk of developing opportunistic fungal infections in patients under treatment with TNF-alpha blockers, because some patients have died read more
2008-09-04	Mitsubishi Tanabe Annual Report 2007	Japanese sales in 2007 of Yen 28.6 bln (+ 39.6 %) = USD 264.3 mln

Files

No files